Blog
RSS FeedPosted by Michael Wonder on 02 Dec 2015
Decision to retain first-line biologic access for adalimumab in dermatology and rheumatology indications
2 December 2015 - PHARMAC is pleased to announce the approval of an agreement with AbbVie Limited to reduce the price ...
Posted by Michael Wonder on 30 Nov 2015
FDA approves Empliciti, a new immune-stimulating therapy to treat multiple myeloma
30 November 2015 - Today the U.S. FDA granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat ...
Posted by Michael Wonder on 25 Nov 2015
Netupitant with palonosetron hydrochloride for the prevention of nausea and vomiting: added benefit not proven says IQWiG
16 November 2015 - According to the findings, an added clinical benefit is not proven in moderately emetogenic or in highly ...
Posted by Michael Wonder on 25 Nov 2015
NICE publishes final drug recommendations for the treatment of four separate medical conditions
25 November 2015 - Each piece of guidance looked at the cost-effectiveness of a particular drug to treat a specific medical ...
Posted by Michael Wonder on 25 Nov 2015
FDA approves Portrazza to treat advanced squamous non-small cell lung cancer
24 November 2015 - The U.S. FDA today approved Portrazza (necitumumab) for use in combination with two forms of chemotherapy to ...
Posted by Michael Wonder on 25 Nov 2015
FDA approves vaccine for use after known or suspected anthrax exposure
24 November 2015 - The vaccine’s new use is approved for people 18 through 65 years of age in conjunction with ...
Posted by Michael Wonder on 25 Nov 2015
NICE draft guidance recommends elosulfase alfa (Vimizim) for treatment of very rare life-limiting genetic disorder under managed access agreement
23 November 2015 - In final draft guidance as part of its Highly Specialised Technologies Programme, NICE has provisionally recommended Elosulfase ...
Posted by Michael Wonder on 23 Nov 2015
Pembrolizumab in advanced melanoma: additional clinical benefit for certain patients says German IQWiG
16 November 2015 - According to the findings, an additional clinical benefit can be derived for different patient groups: in pretreated ...
Posted by Michael Wonder on 23 Nov 2015
FDA approves Opdivo to treat advanced form of kidney cancer
23 November 2015 - The U.S. FDA today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a ...
Posted by Michael Wonder on 21 Nov 2015
Meeting highlights from the Committee for Medicinal Products for Human Use - 16-19 November 2015
20 November 2015 - Ten medicines, including a first-in-class orphan medicine for narcolepsy, recommended for authorisation in the EU. ...
Posted by Michael Wonder on 21 Nov 2015
Narcolepsy treatment recommended for approval
20 November 2015 - Wakix to target excessive daytime sleepiness and cataplexy. ...
Posted by Michael Wonder on 20 Nov 2015
FDA approves Ninlaro, new oral medication to treat multiple myeloma
20 November 2015 - Today the U.S. FDA granted approval for Ninlaro (ixazomib) for use in combination with two other therapies ...
Posted by Michael Wonder on 19 Nov 2015
NICE OK's restricted use of Bayer's prostate cancer drug Xofigo
19 November 2015 - NICE will this morning issue a Final Appraisal Determination recommending the use of Bayer’s Xofigo on the ...
Posted by Michael Wonder on 19 Nov 2015
Tiotropium/olodaterol in COPD: IQWiG finds disadvantages in patients with more severe disease, advantages for some women
16 November 2015 - According to the findings, there were no statistically significant differences between the treatment groups for the totality ...
Posted by Michael Wonder on 19 Nov 2015
FDA moves quickly to approve easy-to-use nasal spray to treat opioid overdose
18 November 2015 - Today the U.S. FDA approved Narcan nasal spray, the first FDA-approved nasal spray version of naloxone hydrochloride, ...